Reply to H. Läubli et al

Affiliations

¹ School of Medicine, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, United Kingdom fergus.macbeth@btinternet.com.
² School of Medicine, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, United Kingdom.

Comment

Fergus R Macbeth et al. J Clin Oncol. 2016.

. 2016 Jul 20;34(21):2561.

doi: 10.1200/JCO.2016.67.7500. Epub 2016 May 16.

¹ School of Medicine, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, United Kingdom fergus.macbeth@btinternet.com.
² School of Medicine, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, United Kingdom.

No abstract available

Comment on

Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial.
Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, Knoyle D, Linnane S, Longo M, Moore B, Woll PJ, Appel W, Dickson J, Ferry D, Brammer C, Griffiths G. Macbeth F, et al. J Clin Oncol. 2016 Feb 10;34(5):488-94. doi: 10.1200/JCO.2015.64.0268. Epub 2015 Dec 23. J Clin Oncol. 2016. PMID: 26700124 Clinical Trial.
Antimetastatic Properties of Low Molecular Weight Heparin.
Läubli H, Varki A, Borsig L. Läubli H, et al. J Clin Oncol. 2016 Jul 20;34(21):2560-1. doi: 10.1200/JCO.2016.66.4607. Epub 2016 May 16. J Clin Oncol. 2016. PMID: 27185851 No abstract available.